Edwards Lifesciences (EW) Stock
Key stats
- Market cap
- $50.78B
- Price / Earnings ratio
- 49.6x
- EPS (TTM)
- $1.74
- Volume
- Loading
- 52-week high
- $96.29
- 52-week low
- $72.40
- EPS vs analyst estimate
- +13.6%Q3 FY25 · $0.67 vs $0.59
- Next earnings report
- 29 Oct 2026
Source: third-party data provider, as of October 17, 2026
EPS estimate: analyst consensus
Compare with EW
Recent news

Edwards Lifesciences to Host Investor Event in Conjunction With TCT
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
EW

Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
EW

Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
EW

Edwards Lifesciences Comments on TAVR National Coverage Decision
Edwards Lifesciences Comments on TAVR National Coverage Decision
EW
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.36
- MACD 12/26/9
- -0.46
- EMA 9 of MACD
- -0.68
- MACD histogram
- 0.22
- SMA 50
- $88.47
- Price below SMA 50
- EMA 50
- $87.36
- Price above EMA 50
- SMA 200
- $85.14
- Price above SMA 200
- EMA 200
- $85.58
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.73 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Edwards Lifesciences to Host Investor Event in Conjunction With TCT
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
EW

Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
EW

Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
EW

Edwards Lifesciences Comments on TAVR National Coverage Decision
Edwards Lifesciences Comments on TAVR National Coverage Decision
EW

Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
EW

Should You Hold Edwards Lifesciences Stock in Your Portfolio?
Should You Hold Edwards Lifesciences Stock in Your Portfolio?
EW

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?
EW

Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
EW

Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
EW

Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
EW
News tone: automated (AI) classification of the article's content, not a price prediction.
About Edwards Lifesciences
Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Bernard J. Zovighian | CEO & Director | 1968 |
| Ms. Theodora Mistras | Corporate VP & CFO | 1982 |
| Mr. Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development | 1962 |
| Mr. Daveen Chopra | Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies | 1979 |
| Ms. Annette Maria Bruls | Corporate Vice President of EMEA, Canada, & Latin America | 1971 |
| Mr. Joseph Nuzzolese | Corporate Vice President of Global Operations & Quality | — |
| Mr. Andrew M. Dahl | Principal Accounting Officer, Senior VP & Corporate Controller | 1978 |
| Dr. Todd Brinton FACC, M.D. | Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer | — |
| Mr. Snehashish Sarkar | Senior VP and Chief Information & Digital Officer | 1975 |
| Mr. Mark D. Peterson | Corporate VP & General Counsel | 1963 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 17, 2026
Technical indicators
- RSI 14
- 54.36
- MACD 12/26/9
- -0.46
- EMA 9 of MACD
- -0.68
- MACD histogram
- 0.22
- SMA 50
- $88.47
- Price below SMA 50
- EMA 50
- $87.36
- Price above EMA 50
- SMA 200
- $85.14
- Price above SMA 200
- EMA 200
- $85.58
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $101.00
- Average
- $106.17
- High
- $110.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +7.9 | -7.1 | +20.6 | |||||||||
| 2022 | -14.9 | +3.7 | +5.5 | -14.0 | -3.8 | -2.3 | +3.2 | -9.4 | -8.3 | -15.2 | +6.4 | -3.8 |
| 2023 | +3.3 | -1.3 | +3.6 | +7.1 | -3.8 | +10.7 | -10.3 | -6.8 | -9.3 | -7.9 | +6.1 | +11.5 |
| 2024 | +3.8 | +7.8 | +12.1 | -10.2 | +3.1 | +5.1 | -30.1 | +13.1 | -4.0 | +2.9 | +5.6 | +5.0 |
| 2025 | -0.2 | +0.3 | +1.5 | +5.0 | +4.0 | +0.1 | +2.8 | +2.5 | -4.9 | +8.0 | +4.3 | -0.0 |
| 2026 | -4.7 | +4.6 | -8.1 | +2.8 | +3.0 | +2.6 | -6.4 | +2.2 | -4.9 | +3.4 |



